22 terminated. 22 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Terminated 22 |
| Phase 2 | 6 | Terminated 6 |
Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 5 | 2023-07-28 | 2026-07-20 |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma EZM0414 - Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Epizyme, Inc. | 13 | 2022-05-31 | 2025-06-22 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma ME-401, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Deepa Jagadeesh | 13 | 2021-04-28 | 2025-02-07 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer SEA-TGT, sasanlimab, brentuximab vedotin - Non-small Cell Lung Cancer, Gastric Carcinoma | Phase 1 | Terminated | Seagen Inc. | 133 | 2020-05-29 | 2025-02-10 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine - Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 18 | 2019-10-24 | 2024-01-03 |
| Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients Tisagenlecleucel, Ibrutinib - Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 10 | 2019-06-11 | 2023-01-31 |
| A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Venetoclax, AMG 176 - Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Terminated | AbbVie | 9 | 2019-03-18 | 2021-12-07 |
| Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Loncastuximab Tesirine and Durvalumab - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 13 | 2019-02-04 | 2021-10-26 |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Loncastuximab Tesirine, Ibrutinib - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | ADC Therapeutics S.A. | 136 | 2018-12-01 | 2024-02-06 |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma Maplirpacept (PF-07901801), Azacitidine, Venetoclax - Lymphoma, Multiple Myeloma | Phase 1 | Terminated | Pfizer | 189 | 2018-05-14 | 2024-09-03 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 3 | 2017-02-01 | 2020-11-23 |
| Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies MAK683 - Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 139 | 2016-10-03 | 2025-08-11 |
| A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Alisertib - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 | Terminated | UNC Lineberger Comprehensive Cancer Center | 1 | 2016-10-01 | 2017-11-20 |
| A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma SGN-CD19B - Non-Hodgkin Lymphoma, DLBCL | Phase 1 | Terminated | Seagen Inc. | 44 | 2016-02-01 | 2018-08-13 |
| Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial rituximab - Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Celltrion | 1 | 2012-02-01 | 2014-07-23 |
Showing 20 of 22. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (22) · Lymphoma (6) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (4) · Burkitt Lymphoma (3) · Neoplasms (3) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, T-Cell, Peripheral (2) · Melanoma (2) · Multiple Myeloma (2)
Hemic and Lymphatic Diseases (22) · Immune System Diseases (22) · Immunoproliferative Disorders (22) · Lymphatic Diseases (22) · Lymphoproliferative Disorders (22) · Neoplasms by Histologic Type (22) · Lymphoma, B-Cell (21) · Neoplasms (19) · Lymphoma, Non-Hodgkin (18) · Lymphoma (16) · Hematologic Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Disease Attributes (5) · DNA Virus Infections (3)
Rituximab (7) · Cyclophosphamide (3) · Doxorubicin (3) · Etoposide (3) · Prednisone (3) · Vincristine (3) · loncastuximab tesirine (3) · Lenalidomide (2) · ibrutinib (2) · venetoclax (2) · Azacitidine (1) · Brentuximab Vedotin (1) · CT-P10 (1) · Carmustine (1) · Cytarabine (1)
Pfizer (4) · ADC Therapeutics S.A. (3) · Novartis Pharmaceuticals (3) · Fred Hutchinson Cancer Center (2) · Seagen Inc. (2) · AbbVie (1) · Antengene Corporation (1) · Celltrion (1) · Deepa Jagadeesh (1) · Epizyme, Inc. (1) · Genmab (1) · National Cancer Institute (NCI) (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (19) · Spain (7) · France (4) · Italy (4) · South Korea (4) · Germany (3) · Japan (3) · United Kingdom (3) · Belgium (2) · Canada (2) · China (2) · Hong Kong (2) · Netherlands (2) · Taiwan (2) · Australia (1)
Ajay Gopal (1) · Andres Forero-Torres, MD (1) · Christopher Dittus, DO (1) · Deepa Jagadeesh, MD, MPH (1) · Juan Pinelli, PA-C, MMSc (1) · Manoj Menon, MD (1) · Wonseog Kim, M.D., Ph.D. (1) · Wyndham H Wilson, M.D. (1)
PMID 28903943, PMID 39793445, PMID 40184567, PMID 41536778
2018 (3), 2019 (2), 2016 (1), P01CA044991 (1), P30CA015704 (1)